Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Clinigen Group Plc LSE:CLIN London Ordinary Share GB00B89J2419 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 925.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
924.50 925.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 523.60 51.80 22.80 40.6 1,234
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 925.00 GBX

Clinigen (CLIN) Latest News

More Clinigen News
Clinigen Investors    Clinigen Takeover Rumours

Clinigen (CLIN) Discussions and Chat

Clinigen Forums and Chat

Date Time Title Posts
19/4/202216:19Clinigen - solid looking growth stock334
24/2/202122:59Clinigen - Speciality Pharmaceuticals1,052

Add a New Thread

Clinigen (CLIN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Clinigen trades in real-time

Clinigen (CLIN) Top Chat Posts

DateSubject
26/6/2022
09:20
Clinigen Daily Update: Clinigen Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker CLIN. The last closing price for Clinigen was 925p.
Clinigen Group Plc has a 4 week average price of 0p and a 12 week average price of 924p.
The 1 year high share price is 945p while the 1 year low share price is currently 541.50p.
There are currently 133,366,726 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Clinigen Group Plc is £1,233,642,215.50.
17/1/2022
09:25
kenmitch: The lower share price well below that 925p higher offer, reflects the risk of the bid failing. IF it does the share pice could well fall quite heavily, giving a great chance for those of us who sold recently a chance to buy again. There’s also the chance of a new bidder and a bidding war......but bearing in mind the share price drifting lower last week and down again today, suggests the market (which is often a good guide in bid situations) thinks this is unlikely. So investors deciding to continue to hold could do very well.....but also risk significant share price fall. Those who’ve sold have surely done very well and have banked those gains.
05/1/2022
08:55
paying4it: Are things looking good for a better offer ?Read this online this morning Private equity bidder under pressure to raise Clinigen offerBid for pharmaceutical company ClinigenElliot Gulliver-Needham clock05 January 2022• 1 min readSHAREtwitter-iconlinkedin iconfacebook-iconwhatsapp-icon Private equity bidder under pressure to raise Clinigen offerImage: Private equity bidder under pressure to raise Clinigen offerPressure has mounted on private equity firm Triton Investment Management to raise its offer on its £1.2bn bid for pharmaceutical company Clinigen.Triton's 833p-per-share offer was made last month after recommendation from Clinigen's board, giving a 41% premium on Clinigen's ex-dividend share price before the offer period began.However, investors in the company, such as hedge fund Elliott Management, are arguing that the company's current share price of 916p shows that the company has been undervalued.Other investors which are thought to be arguing that the company is undervalued includes Sparta Capital, another activist fund, and Carlson Capital, which holds a position in Clinigen through derivatives.Amundi reframes business post Lyxor acquisitionElliott Management, run by billionaire co-CEO Paul Singer, recently caused controversy by publicly attacking the energy firm SSE over its energy transition strategy.The hedge fund owns 9.8% of Clinigen and is understood to have previously pressed management to consider a break-up of the company.The scheme document detailing the takeover was issued to shareholders before the vote on 18 January, while also showing that Clinigen expects to pay £14.1m in fees to advisers for the deal.
09/12/2021
09:12
tomps2: Andy Brough interview with PIWORLD Andy Brough mentions Clinigen #CLIN in the latest PIWORLD interview at 17m18s then again at 19m Watch the video here: Https://www.piworld.co.uk/education-videos/piworld-interview-with-andy-brough-markets-lessons-learned-in-2021/ Or listen to the Podcast here: Https://piworld.podbean.com/e/piworld-interview-with-andy-brough-markets-lessons-learned-in-2021/
08/12/2021
10:33
hjs: Ken I agree with what you are saying but I would also add that the "bidder" normally starts with a lower bid. They have the fair value in their DD and based on that figure, they have the flexibility of offering more if needed or there is a rival bid. IMO, based on the reaction of the share price, market thinks there is a rival bidder or the bid will be raised. I do not think one should rush and sell at this price. We have to wait and see what happens in the next few weeks.
08/12/2021
09:25
kenmitch: When the share price goes usefully higher than the price of the agreed bid, it means the market thinks there may be one or maybe more rival bids. Bidding wars are great fun for investors holding that share. Sometimes there is a rival higher bid and sometimes there isn’t but, as has happened with the CLINIGEN share price in recent days, sometimes the market does know what is going on behind the scenes, presumably from chat etc with one or more of those in the know. There’s probably no rush to sell yet. There is now a floor under the share price, unless the bidder walks away which right now seems unlikely. If the share price drops to just below the price of the now agreed bid, that strongly hints that there are unlikely to be any rival bids.
08/12/2021
08:53
hjs: Share price is higher than the offer price because Inst. shareholders know that this company has been sold off cheaply than its fair value. They will not give in and accept the offer price.
08/12/2021
08:46
r2oo: Just sold my stake at a 27 percent profit so happy with that.This but out looks like a done deal and yet the share price is currently at a premium to what share holders will receive if they hold out until the deal is done.
01/12/2021
13:08
b1nky: Anyone know/understand what's going on with share price?
24/11/2021
18:33
value viper: No trading update but clear dissent with institutional investors re pay and director roles - not surprising frankly. The share price performance is dire for what they get paid etc - all aligned with Elliott's now involvement - change is needed
16/9/2021
21:50
whatja: Well that is a second warning, although interspersed with some hope. The product division appears to be the problem….big bet placed on proleukin is not coming good.it May recover but the longer the disruption continues, the greater the chances that a better product takes market share. The share price will recover when the health sector normalises or the company limps along for a couple of years and is sufficiently strong to take a write down…it can then get out from that shadow. The number of wins for services such as cliniport show the potential for a better cleaner business….but what is it worth on a sum of the parts basis broken up? Beware a cheap MBO backed by PE of the good division leaving the rump as a zombie.
Clinigen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
CLIN
Clinigen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220626 13:52:34